JP2017508744A5 - - Google Patents

Download PDF

Info

Publication number
JP2017508744A5
JP2017508744A5 JP2016555329A JP2016555329A JP2017508744A5 JP 2017508744 A5 JP2017508744 A5 JP 2017508744A5 JP 2016555329 A JP2016555329 A JP 2016555329A JP 2016555329 A JP2016555329 A JP 2016555329A JP 2017508744 A5 JP2017508744 A5 JP 2017508744A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
inhibitor
composition according
activity
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016555329A
Other languages
English (en)
Japanese (ja)
Other versions
JP6538707B2 (ja
JP2017508744A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2015/001033 external-priority patent/WO2015132675A2/en
Publication of JP2017508744A publication Critical patent/JP2017508744A/ja
Publication of JP2017508744A5 publication Critical patent/JP2017508744A5/ja
Application granted granted Critical
Publication of JP6538707B2 publication Critical patent/JP6538707B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016555329A 2014-03-07 2015-03-06 免疫応答を調節するための方法及び組成物 Expired - Fee Related JP6538707B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461949927P 2014-03-07 2014-03-07
US61/949,927 2014-03-07
PCT/IB2015/001033 WO2015132675A2 (en) 2014-03-07 2015-03-06 Methods and compositions for modifying the immune response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019106087A Division JP2019147839A (ja) 2014-03-07 2019-06-06 免疫応答を調節するための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2017508744A JP2017508744A (ja) 2017-03-30
JP2017508744A5 true JP2017508744A5 (enExample) 2018-05-31
JP6538707B2 JP6538707B2 (ja) 2019-07-03

Family

ID=54016312

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016555329A Expired - Fee Related JP6538707B2 (ja) 2014-03-07 2015-03-06 免疫応答を調節するための方法及び組成物
JP2019106087A Pending JP2019147839A (ja) 2014-03-07 2019-06-06 免疫応答を調節するための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019106087A Pending JP2019147839A (ja) 2014-03-07 2019-06-06 免疫応答を調節するための方法及び組成物

Country Status (8)

Country Link
US (3) US20150252434A1 (enExample)
EP (2) EP3113798B1 (enExample)
JP (2) JP6538707B2 (enExample)
KR (1) KR20160127817A (enExample)
AU (1) AU2015225867B2 (enExample)
CA (3) CA2941697A1 (enExample)
IL (1) IL247614B (enExample)
WO (3) WO2015132675A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
US20150252434A1 (en) 2014-03-07 2015-09-10 University Health Network Methods and compositions for detection of targets involved in cancer metastasis
ES2690420T3 (es) * 2015-05-28 2018-11-20 Universität Zu Köln Receptor de antígeno quimérico anti-toso y su uso
EP3668876B1 (en) 2017-08-18 2024-01-24 Cothera Bioscience, Inc. Polymorphic form of tg02
BR112021014112A2 (pt) 2019-01-18 2021-10-13 Dracen Pharmaceuticals, Inc. Usos de composto pró-fármaco de don e inibidor de ponto de controle imunológico para tratar câncer, bem como composto e composição farmacêutica compreendendo o mesmo
TWI857009B (zh) * 2019-02-15 2024-10-01 大學健康網絡 Ｆｃｍｒ結合分子及其用途
US12570679B2 (en) 2019-03-29 2026-03-10 Regents Of The University Of Michigan STAT3 protein degraders
US20220218847A1 (en) * 2019-04-23 2022-07-14 The Broad Institute, Inc. Compositions and methods characterizing metastasis
US20220265590A1 (en) 2019-06-12 2022-08-25 Vanderbilt University Dibenzylamines as amino acid transport inhibitors
AU2020291464A1 (en) 2019-06-12 2022-02-03 Vanderbilt University Amino acid transport inhibitors and the uses thereof
BR112021026334A2 (pt) 2019-06-27 2022-05-10 Medstar Health Macrófagos ativados por hdac6, composições, e usos dos mesmos
AU2020315401B2 (en) 2019-07-16 2025-05-22 The Regents Of The University Of Michigan Imidazopyrimidines as EED inhibitors and the use thereof
JP7196798B2 (ja) 2019-08-09 2022-12-27 株式会社Soken 超音波センサ
US20220388978A1 (en) 2019-08-27 2022-12-08 Regents Of The University Of Michigan Cereblon e3 ligase inhibitors
CA3176606A1 (en) * 2020-03-26 2021-09-30 Cureimmune Therapeutics Inc. Anti-pd-1 antibodies and methods of use
WO2021195481A1 (en) 2020-03-26 2021-09-30 The Regents Of The University Of Michigan Small molecule stat protein degraders
US20240166647A1 (en) 2021-03-03 2024-05-23 The Regents Of The University Of Michigan Cereblon Ligands
WO2025151487A2 (en) 2024-01-08 2025-07-17 Regents Of The University Of Michigan Small-molecule inhibitors of adar1

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3546807C2 (enExample) 1985-03-30 1991-03-28 Marc Genf/Geneve Ch Ballivet
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5686073A (en) 1990-05-23 1997-11-11 The University Of Iowa Research Foundation Polyclonal and monoclonal antibodies against a 43 KDA dystrophin associated protein
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
DE69232859T2 (de) 1991-09-13 2003-04-10 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Zusammensetzung aus mehreren immunreaktiven hepatitis-c-virus-polypeptiden
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
JP4157160B2 (ja) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド 改変抗体可変領域の調製のための方法
US5455338A (en) 1993-11-05 1995-10-03 Zymogenetics, Inc. DNA encoding novel human kunitz-type inhibitors and methods relating thereto
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
US6709659B1 (en) 1996-08-02 2004-03-23 Zymogenetics, Inc. Antibodies that bind testis-specific insulin homolog polypeptides
US6727350B2 (en) * 1997-11-17 2004-04-27 The Board Of Trustees Of The Leland Stanford Junior University Toso
US6555314B1 (en) * 1998-03-30 2003-04-29 Rigel Pharmaceuticals, Inc. Toso as a target for drug screening
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6322788B1 (en) 1998-08-20 2001-11-27 Stanley Arthur Kim Anti-bacterial antibodies and methods of use
DE69938054T2 (de) 1998-11-18 2009-02-12 Genentech, Inc., South San Francisco Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
PT1176195E (pt) 1999-04-09 2013-07-18 Kyowa Hakko Kirin Co Ltd Processo para controlar a actividade de uma molécula funcional sob o ponto de vista imunológico
US6939545B2 (en) 1999-04-28 2005-09-06 Genetics Institute, Llc Composition and method for treating inflammatory disorders
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
EP2298789B1 (en) 2000-09-08 2012-03-14 Schering Corporation Mammalian genes; related reagents and methods
WO2002030954A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kogyo Co., Ltd. Method of purifying antibody
DK2314686T4 (da) 2000-10-06 2023-08-21 Kyowa Kirin Co Ltd Celler, der danner antistofsammensætninger
US20020127557A1 (en) * 2001-03-09 2002-09-12 Ruoying Tan Method for identification of cDNAs encoding signal peptides
EP1450602B1 (en) * 2001-03-28 2008-08-27 Dana-Farber Cancer Institute, Inc. Identifying and characterizing genes
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
US7119179B1 (en) 2005-03-21 2006-10-10 Los Alamos National Security, Llc Preparation of high nitrogen compound and materials therefrom
WO2009158620A2 (en) * 2008-06-26 2009-12-30 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with metastasis methods of use thereof
JP2012517821A (ja) * 2009-02-19 2012-08-09 ガラパゴス・ナムローゼ・フェンノートシャップ 炎症を包含する疾患の診断及び治療に有用な同定方法及び化合物
US10817851B2 (en) 2009-12-23 2020-10-27 Aristocrat Technologies Australia Pty Limited System and method for cashless gaming
US9228006B2 (en) * 2012-03-16 2016-01-05 University Health Network Methods and compositions for modulating Toso activity
DK2831095T3 (en) * 2012-03-30 2019-02-18 Immune Design Corp LENTIVIRAL VECTOR PARTICLES WITH IMPROVED TRANSDUCTION EFFICIENCY FOR CELL EXPRESSING DC SIGN
US20140294792A1 (en) * 2013-02-22 2014-10-02 The Board Of Trustees Of The University Of Illinois T-REG Cell Expansion
US20150252434A1 (en) 2014-03-07 2015-09-10 University Health Network Methods and compositions for detection of targets involved in cancer metastasis

Similar Documents

Publication Publication Date Title
PE20190911A1 (es) Composiciones y anticuerpos anti-lag-3
RU2016107426A (ru) Комбинирование агонистов cd27 и ингибирование иммунных контрольных точек для стимуляции иммунитета
Okoye et al. Coinhibitory receptor expression and immune checkpoint blockade: maintaining a balance in CD8+ T cell responses to chronic viral infections and cancer
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
JP2019508444A5 (enExample)
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
JP2017534633A5 (enExample)
HRP20221135T1 (hr) KOMBINACIJE mRNK KOJE KODIRAJU IMUNOMODULIRAJUĆE POLIPEPTIDE I NJIHOVE UPOTREBE
JP2018515474A5 (enExample)
JP2018508483A5 (enExample)
JP2016531907A5 (enExample)
EA201791675A1 (ru) Человеческие антитела к гликопротеину вируса эбола
JP2017524348A5 (enExample)
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
HRP20190881T1 (hr) Kombinacijska terapija s hijaluronan-razgrađujućim enzimom i inhibitorom imunološke kontrolne točke
JP2018520679A5 (enExample)
MY200849A (en) Anti-Icos Agonist Antibodies and uses Thereof
HRP20230060T1 (hr) Antitijela protiv ox40 i njihova primjena
SG10201805411YA (en) Chimeric antigen receptors
PH12018500664A1 (en) Anti-lag3 antibodies and uses thereof
RU2021114500A (ru) НАПРАВЛЕННОЕ ИНГИБИРОВАНИЕ TGFβ
EA201690567A1 (ru) Антитела против pd1 и их применение в качестве терапевтических и диагностических средств
JP2018514550A5 (enExample)
RU2015139969A (ru) Комбинация вакцинации и ингибирования пути pd-1
Lynch et al. Adoptive transfer of murine T cells expressing a chimeric‐PD 1‐Dap10 receptor as an immunotherapy for lymphoma